Publications

1. Palaniraja S, Taghavi K, Kataria I, Oswal K, Vani NV, Liji AA, et al. (2025). Barriers and contributions of rural community health workers in enabling cancer early detection and subsequent care in India: a qualitative study. BMC Public Health. 25(1):1527. https://doi.org/10.1186/s12889-025-22735-y PMID:40275281
2. Fuady A, Kasempa C, Lucas E, Nyambe N, Rao DW, Tenet V, et al. (2025). Economic evaluation of thermal ablation compared to cryotherapy and loop diathermy in a screen-and-treat approach to cervical cancer, Zambia. Bull World Health Organ. 103(9):530–40. https://doi.org/10.2471/BLT.24.292792 PMID:40900929
3. Joshi S, Muwonge R, Bhosale R, Chaudhari P, Kulkarni V, Mandolkar M, et al. (2025). A randomised controlled non-inferiority trial to compare the efficacy of ‘HPV screen, triage and treat’ with ‘HPV screen and treat’ approach for cervical cancer prevention among women living with HIV. Nat Commun. 16(1):1888. https://doi.org/10.1038/s41467-025-56926-3 PMID:39987163
4. Chandran A, Mackie A, Sasieni P, Arbyn M, Carvalho AL, Chauvet C, et al.; CervScreen Technical Working Group (2025). Technical, legal and ethical framework of cancer audit in cervical screening – summary of best practices for organised programmes delineated through an expert group consultation. Int J Cancer. 157(1):32–40. https://doi.org/10.1002/ijc.35403 PMID:40208390
5. Malvi SG, Esmy PO, Muwonge R, Joshi S, Poli URR, Lucas E, et al. (2024). A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination. J Natl Cancer Inst Monogr. 2024(67):317–28. https://doi.org/10.1093/jncimonographs/lgae042 PMID:39529521
6. Chandran A, Togawa K, Mosquera I, Selmouni F, Dimitrova N, Lucas E, et al. (2026). From evidence to action: the IARC’s role in strengthening cancer prevention and early detection. J Natl Cancer Inst Monograph. 2026(72):69–77. https://doi.org/10.1093/jncimonographs/lgag001 PMID:42008725
7. Ramírez AT, Clifford GM, Dillner J, Kuhn L, Arbyn M, Bhatla N, et al. (2025). Reflections regarding validation of new HPV tests with reduced HPV genotypes: report from an IARC expert consultation. J Med Virol. 97(3):e70310. https://doi.org/10.1002/jmv.70310 PMID:40109087
8. Singh D, Carvalho AL, Mosquera I, Vilaseca J, Patasius A, Miksiene G, et al.; PRAISE-U consortium (2025). Monitoring of prostate cancer screening in the European Union: development of key performance indicators through the PRAISE-U project. EClinicalMedicine. 80:103022. https://doi.org/10.1016/j.eclinm.2024.103022 PMID:39927107
9. Man I, Georges D, Basu P, Baussano I (2024). Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings. J Natl Cancer Inst Monogr. 2024(67):400–9. https://doi.org/10.1093/jncimonographs/lgae035 PMID:39529528
10. Mosquera I, Chandran A, Rol ML, Mesmin Olivier AY, Herve Julius YB, Asnake TM, et al. (2025). Assessment of barriers to the cervical cancer continuum and existing interventions in 5 African countries. BMC Public Health. 26(1):111. https://doi.org/10.1186/s12889-025-25733-2 PMID:41345850
11. Mosquera I, Theriault H, Meunier D, Basu P, Carvalho AL (2025). Development and pilot testing of INTERVENER, a web-based tool to match barriers to the cancer continuum organization to evidence-based interventions. BMC Health Serv Res. 25(1):47. https://doi.org/10.1186/s12913-024-12171-w PMID:39789584
12. Park JY, Georges D, Alberts CJ, Bray F, Clifford G, Baussano I (2025). Global lifetime estimates of expected and preventable gastric cancers across 185 countries. Nat Med. 31(9):3020–7. https://doi.org/10.1038/s41591-025-03793-6 PMID:40624406
13. Roux A, Hervouet L, Stefano FD, French DP, Giordano L, Ritchie D, et al.; MyPeBS Investigators and the MyPeBS Consortium (2025). Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study. BMC Cancer. 25(1):483. https://doi.org/10.1186/s12885-025-13848-z PMID:40089664 [Erratum in: BMC Cancer. 2025 Apr 14;25(1):687. https://doi.org/10.1186/s12885-025-13994-4 PMID:40229693]
14. Sheikh M, Domingues A, Alcala K, Langdon R, Mariosa D, Feng X, et al. (2025). Regular use of pharmaceutical opioids and subsequent risk of cancer: a prospective cohort study and Mendelian randomization analysis. EClinicalMedicine. 89:103439. https://doi.org/10.1016/j.eclinm.2025.103439 PMID:41357337
15. Alberts CJ, Georges D, Bray F, Bordoni A, Aresté MC, Chirlaque López MD, et al. (2026). A European collaborative initiative to systematically map cancer risk by migration background: the Cancer RADAR project. Int J Equity Health. https://doi.org/10.1186/s12939-026-02899-8 PMID:42226257
16. Feng X, Guida F, Guenoun A, Alcala K, Aldrich MC, Arslan AA, et al. (2026). Performance of lung cancer risk prediction models in different racial and ethnic groups in the United States: results from the Lung Cancer Cohort Consortium. Ann Intern Med. https://doi.org/10.7326/ANNALS-25-03816 PMID:42372272
17. Nemati S, Vand Rajabpour M, Feng X, Taheri N, Rumgay H, Heidari F, et al. (2026). Tobacco control policies on cancer prevention in the Eastern Mediterranean Region, 2025–2050: a modeling study. PLoS Med. 23(4):e1005032. https://doi.org/10.1371/journal.pmed.1005032 PMID:42030293
18. Park JY, Lee YC, Moayyedi P, Lansdorp-Vogelaar I, Camargo MC, Tepeš B, et al. (2026). Helicobacter pylori screen-and-treat programs for gastric cancer prevention – IARC Working Group Report. N Engl J Med. 394(11):1131–7. https://doi.org/10.1056/NEJMsb2515372 PMID:41812202
19. Wen T, Dong L, Li J, Feng Y, Nie L, Li Z, et al. (2026). Memory cell and antibody responses following a single versus two doses of Escherichia coli-produced vaccine against human papillomavirus types 16 and 18: a real-world study in Chinese girls. Int J Cancer. https://doi.org/10.1002/ijc.70553 PMID:42163577
20. Zahed H, Feng X, Alcala K, Smith-Byrne K, Moez E, Guida F, et al. (2026). Biomarker-based eligibility for lung cancer screening: validation of the protein-based INTEGRAL-Risk model. JAMA. e268044. https://doi.org/10.1001/jama.2026.8044 PMID:42149699